SINO BIOPHARM

China Biopharmaceutical Co., Ltd. (the “Company” or “China Biopharmaceutical”) and its subsidiaries (the “Group”) is a leading innovative research and development-driven pharmaceutical group in China. Its business covers the entire industry chain of pharmaceutical R&D platforms, intelligent production and a strong sales system. The products include a variety of biopharmaceuticals and chemicals, and are in an advantageous position in the four major treatment fields of cancer, liver disease, respiratory system, and surgery/analgesia.

The Company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a constituent stock of the MSCI Global Standard Index in 2013; selected as a constituent stock of the Hang Seng China Enterprise Index in 2018; selected as a constituent stock of the Hang Seng China Enterprise Index in 2019; as a constituent stock of the Hang Seng Shanghai-Shenzhen-Hong Kong Stock Connect Biotech 50 Index and Hang Seng China (Hong Kong Listed) 25 Index in 2020. China Biopharmaceuticals has been ranked in the “Top 50 Global Pharmaceutical Companies” published by the authoritative American magazine “Pharmaceutical Manager” for 5 consecutive years, and has been named “Top 50 Best Companies in Asia Pacific” by “Forbes” (Asia) for 3 consecutive years.

Chinese biopharmaceutical companies are distributed in Beijing, Shanghai, Nanjing, Lianyungang, etc., and have multiple pharmaceutical production bases. Since its establishment, the company has continued to achieve outstanding achievements and steady development. The core member companies, Zhengda Tianqing Pharmaceutical Group Co., Ltd., and Beijing Tide Pharmaceutical Co., Ltd. have all been on the list of China's top 100 pharmaceutical industry enterprises for many years.

The company takes replication as the foundation, comprehensively transforms to innovation, drives growth, and its share of revenue is increasing year by year; the internal research pipeline drives innovation and transformation, continuously improving the technology platform; and actively promotes the internationalization process under the leadership of a top scientific team to seize the international frontier circuit.

China Biopharmaceuticals will adhere to the mission of “health technology to warm more lives”, focus on innovation, serve patients, and strive to become the world's leading pharmaceutical company. We hope to share the development achievements of the medical and health industry with people of insight, and make every effort to cooperate and win the future together!

The Group's main subsidiaries include Zhengda Tianqing Pharmaceutical Group Co., Ltd. (“Zhengda Tianqing”), Beijing Tide Pharmaceutical Co., Ltd. (“Beijing Tide”), Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. (“Nanjing Zhengda Tianqing”), Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd. (“Jiangsu Zhengda Qingjiang”), and InvoX Pharma Limited (“InvoX”). Nanjing Zhengda Tianqing, Jiangsu Zhengda Qingjiang, and Jiangsu Zhengda Fenghai were recognized by the Jiangsu Provincial Science and Technology Department as “Jiangsu Anti-tumor and Cardiovascular Phytochemical Pharmaceutical Engineering Technology Research Center”, “Orthopedic Pharmaceutical Formulation Engineering Technology Research Center”, and “Parenteral Nutrition Engineering Technology Research Center” by the Jiangsu Provincial Department of Science and Technology, respectively.

The Chia Tai Tianqing R&D Center is a “postdoctoral research workstation” granted by the Chinese Ministry of Social Affairs. It is the only “novel liver disease drug engineering technology research center” in China.

Beijing Tide once again obtained GMP certification from Japan's Ministry of Health, Labor, and Welfare for foreign pharmaceutical companies in December 2012. Japanese pharmaceutical companies can entrust Beijing Tide to manufacture and export sterile pharmaceutical preparations under development and already on the market in Japan to Japan.